uniQure to advance AMT-061

uniQure (Nasdaq: QURE) will advance AMT-061 into a pivotal study in 2018 for patients with severe and moderately severe hemophilia B. Shares of the biopharmaceutical leaped $5.69 to close at $15.16.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.